Fockens P, Bruno M J, Gabbrielli A, Odegaard S, Hatlebakk J, Allescher H D, Rösch T, Rhodes M, Bastid C, Rey J, Boyer J, Muehldorffer S, van den Hombergh U, Costamagna G
Academic Medical Center, Amsterdam, The Netherlands.
Endoscopy. 2004 Aug;36(8):682-9. doi: 10.1055/s-2004-825665.
The safety and effectiveness of the Gatekeeper Reflux Repair System (Medtronic Europe, Tolochenaz, Switzerland) in the treatment of gastroesophageal reflux disease (GERD) was evaluated. This new, reversible treatment modality involves the endoscopic introduction of expandable polyacrylonitrile-based hydrogel prostheses into the esophageal submucosa to augment the lower esophageal sphincter (LES).
For this study, data from two prospective, nonrandomized European multicenter trials were pooled. Sixty-nine GERD patients with heartburn and regurgitation and abnormal esophageal acid exposure (24-h pH < 4.0 for > 4 % of the total time) who had responded to proton-pump inhibitor (PPI) therapy were recruited, and 68 were treated with up to six prostheses placed at the gastroesophageal junction. Patients underwent esophageal manometry, endoscopy, 24-h pH-metry, and symptom scoring at intake and 1, 3, and 6 months after the procedure.
A total of 77 procedures were performed in 67 patients, and a total of 270 prostheses were placed (mean 4.3 per procedure). At 1 and 6 months, 80.4 % and 70.4 % of the prostheses were retained, respectively. At 6 months, 24-h pH-metry outcomes with pH < 4.0 for > 4.0 % of the time decreased from 9.1 % to 6.1 % (n = 45; P < 0.05). Median LES pressure increased significantly from 8.8 mmHg at baseline to 13.8 mmHg at 6 months (n = 42, P < 0.01). Median GERD heartburn-related quality-of-life scores improved significantly from 24.0 to 5.0 (n = 53, P < 0.01) in patients no longer receiving PPI therapy. Two serious adverse events (3.0 %) occurred. Both patients recovered uneventfully. Prostheses were endoscopically removed from one patient without any adverse events.
The Gatekeeper Reflux Repair System is a safe endoscopic treatment modality that significantly improves GERD symptoms and has objective effects on acid reflux.
评估Gatekeeper反流修复系统(美敦力欧洲公司,瑞士托洛谢纳兹)治疗胃食管反流病(GERD)的安全性和有效性。这种新型的可逆治疗方式是通过内镜将可膨胀的聚丙烯腈基水凝胶假体植入食管黏膜下层,以增强食管下括约肌(LES)。
本研究汇总了两项前瞻性、非随机的欧洲多中心试验的数据。招募了69例有烧心和反流症状且食管酸暴露异常(24小时pH值<4.0的时间超过总时间的4%)且对质子泵抑制剂(PPI)治疗有反应的GERD患者,其中68例患者在胃食管交界处植入了多达6个假体进行治疗。患者在入组时以及术后1、3和6个月接受食管测压、内镜检查、24小时pH值监测和症状评分。
67例患者共进行了77次手术,共植入270个假体(平均每次手术4.3个)。在1个月和6个月时,分别有80.4%和70.4%的假体留存。在6个月时,24小时pH值监测结果显示pH值<4.0的时间超过4.0%的情况从9.1%降至6.1%(n = 45;P < 0.05)。LES压力中位数从基线时的8.8 mmHg显著增加至6个月时的13.8 mmHg(n = 42,P < 0.01)。在不再接受PPI治疗的患者中,GERD烧心相关生活质量评分中位数从24.0显著改善至5.0(n = 53,P < 0.01)。发生了两例严重不良事件(3.0%)。两名患者均顺利康复。对一名患者进行了内镜下取出假体,未发生任何不良事件。
Gatekeeper反流修复系统是一种安全的内镜治疗方式,可显著改善GERD症状,并对酸反流有客观疗效。